Analysis of the Safety Profile of Commonly Used Procoagulants Using the FDA Adverse Event Reporting System

被引：0
|
作者：
Deloughery, Emma P. [1 ]
Shatzel, Joseph J. [2 ]
机构：
[1] Mayo Clin, Sch Med, Rochester, MN USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-109822
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4712
引用
收藏
页数：3
相关论文
共 50 条
  • [21] COMMONLY REPORTED ADVERSE EVENTS ASSOCIATED WITH ANTICOAGULANTS USING FDA ADVERSE EVENT REPORTING SYSTEM DATABASE 2012-2018
    Costa, L.
    Hincapie, A.
    Guo, J. J.
    [J]. VALUE IN HEALTH, 2019, 22 : S163 - S163
  • [22] Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
    Huang, Jing
    Meng, Long
    Yang, Bing
    Sun, Shusen
    Luo, Zhigang
    Chen, Hong
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [23] Real-world safety profile of eculizumab: an analysis of FDA adverse event reporting system and systematic review of case reports
    Zhang, Zhihui
    Liu, Xin
    Zhang, Jinlan
    Zhang, Bo
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [24] Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system
    Jin, Yiyi
    Fan, Miao
    Zheng, Xiaomeng
    Zhu, Suyan
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [25] Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
    Jing Huang
    Long Meng
    Bing Yang
    Shusen Sun
    Zhigang Luo
    Hong Chen
    [J]. Scientific Reports, 10
  • [26] Post-marketing safety of checkpoint inhibitors: analysis of the FDA adverse event reporting system
    Elias, Rawad
    Rider, Jennifer
    Rahma, Osama
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [27] SAFETY PROFILE OF AMIODARONE AND DRONEDARONE: A PHARMACOEPIDEMIOLOGIC ANALYSIS USING FDA ADVERSE EVENTS REPORTING SYSTEM (FAERS) DATABASE
    Damachi, U.
    Hincapie, A.
    Guo, J.
    [J]. VALUE IN HEALTH, 2019, 22 : S138 - S139
  • [28] Safety of Bempedoic Acid: Post-marketing Analysis of the FDA Adverse Event Reporting System
    Raschi, E.
    Fusaroli, M.
    Forni, M.
    Goldman, A.
    Cicero, A. F. G.
    Poluzzi, E.
    Ponti, F. D.
    [J]. DRUG SAFETY, 2022, 45 (10) : 1287 - 1288
  • [29] A Review of Dental Adverse Events Using the FDA Adverse Event Reporting System
    Altman, Keith
    Budny, Renata
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 400 - 400
  • [30] Post-marketing safety profile of cannabis products: Signals from the FDA adverse event reporting system
    Giunchi, Valentina
    Fusaroli, Michele
    Lunghi, Carlotta
    Zongo, Arsene
    Raschi, Emanuel
    Poluzzi, Elisabetta
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 222 - 223
12345